Rainbow Research Inc — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$4,315	3
2021	Research	$25,968	12
2020	Research	$25,534	7
2019	Research	$63	1

Breakdown

Who paid Research payments · program years 2019–2022

Purdue Pharma L.P. $25,388 14 payments
Takeda Pharmaceuticals U.S.A., Inc. $12,527 3 payments
Adlon Therapeutics L.P. $12,232 3 payments
GlaxoSmithKline, LLC. $4,896 1 payment
Novartis Pharmaceuticals Corporation $839 2 payments

Studies the money was for Research payments · program years 2019–2022

Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $21,073 11 payments
Ada4003 $12,232 3 payments
A Phase 3, Open-Label, Multicenter, 12-Month Safety and Tolerability Study of Spd489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-Deficit / Hyperactivity Disorder $10,832 1 payment
A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T $4,896 1 payment
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $4,315 3 payments
Safety and Tolerability Study of Shp465 in Children Aged 4 to 12 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (Adhd) $1,695 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2B Dose-Finding Study to Investigate the Efficacy and Safety of Ligelizumab (Qge031) in Adolescent Patients With Chronic Spontaneous Urticaria (Csu) $839 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.